LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Abierto

SectorSanidad

3.08 -7.51

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.06

Máximo

3.3

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+521.12% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-73M 316M
Apertura anterior	10.59
Cierre anterior	3.08

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

90 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 may 2026, 23:46 UTC

Charlas de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 may 2026, 23:33 UTC

Charlas de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 may 2026, 22:37 UTC

Charlas de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 may 2026, 22:32 UTC

Ganancias

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 may 2026, 22:02 UTC

Charlas de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 may 2026, 21:49 UTC

Ganancias

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 may 2026, 21:42 UTC

Charlas de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 may 2026, 21:23 UTC

Adquisiciones, fusiones, absorciones

CSG Systems Sale to NEC Gets CFIUS Clearance

11 may 2026, 21:12 UTC

Ganancias

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 may 2026, 21:12 UTC

Ganancias

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 may 2026, 20:44 UTC

Ganancias

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 may 2026, 20:43 UTC

Ganancias

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Rev $136.4M >CLSK

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Cont Ops EPS $2.24 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Rev $1.6B >STE

11 may 2026, 20:30 UTC

Ganancias

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Adj EPS $2.83 >STE

11 may 2026, 20:22 UTC

Acciones populares

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 may 2026, 19:37 UTC

Ganancias

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 may 2026, 19:32 UTC

Charlas de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

521.12% repunte

Estimación a 12 Meses

Media 20 USD 521.12%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

90 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.